Liquidia Corporation

Executive Summary

Liquidia Corporation is a late-stage biopharmaceutical company focused on developing and commercializing therapies for pulmonary diseases using its proprietary PRINT® particle engineering platform. Its lead product, YUTREPIA™ (treprostinil) inhalation powder, has received FDA approval for the treatment of pulmonary arterial hypertension (PAH) but has not yet been commercially launched. The company is also advancing LIQ861, an inhaled dry powder formulation of treprostinil, which may offer differentiated benefits. Liquidia's platform enables precise particle design, potentially improving drug delivery and patient outcomes. With a strong focus on unmet needs in PAH, Liquidia is well-positioned to capture market share upon successful commercialization. The company's near-term value is driven by the launch of YUTREPIA, pipeline progress, and potential partnerships.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of YUTREPIA85% success
• 2027Phase 3 data or NDA submission for LIQ86160% success
• TBDPotential partnership or licensing deal for YUTREPIA or LIQ86150% success